Gene expression profile of ewing sarcoma cell lines differing in their EWS-FLI1 fusion type
Bandrés E, Malumbres R, Escalada A, Cubedo E, González I, Honorato B, Zarate R, García-Foncillas J, de Alava E.
Laboratory of Pharmacogenomics, University of Navarra, Pamplona, Spain
Magazine: Journal of Pediatric Hematology/Oncology
Date: Oct 1, 2005Clinical Genetics Unit [SP]
The t(11;22)(q24;q12) translocation is present in up to 95% of Ewing tumor patients and results in the formation of an EWS-FLI-1 fusion gene that encodes a chimeric transcription factor. Many alternative forms of EWS-FLI-1 exist because of variations in the location of the EWS and FLI-1 genomic breakpoints.
Previous reports have shown that the type 1 fusion is associated with a significantly better prognosis than the other fusion types. It has been suggested that the observed clinical discrepancies result from different transactivation potentials of the various EWS-FLI-1 fusion proteins. In an attempt to identify genes whose expression levels are differentially modulated by structurally different EWS-FLI-1 transcription factors, we have used microarray technology to interrogate 19,000 sequence genes to compare gene expression profile of type 1 or non-type 1 Ewing sarcoma cell lines.
Data analysis showed few qualitative differences on gene expression; expression of only 41 genes (0.215% of possible sequences analyzed) differed significantly between Ewing tumor cell lines carrying EWS-FLI-1 fusion type 1 with respect to those with non-type 1 fusion.
CITATION J Pediatr Hematol Oncol. 2005 Oct;27(10):537-42
you maybe interested
The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.
The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.
Learn why we are different from other healthcare centers. Quality, speed, comfort and results.